Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Kidney International

Volumn 88, Issue 5, 2015, Pages 1135-1143

  Cohen, Camille ^a   Royer, Bruno ^b   Javaugue, Vincent ^c   Szalat, Raphael ^d   El Karoui, Khalil ^a   Caulier, Alexis ^b   Knebelmann, Bertrand ^a   Jaccard, Arnaud ^e   Chevret, Sylvie ^d   Touchard, Guy ^c   Fermand, Jean Paul ^d   Arnulf, Bertrand ^d   Bridoux, Frank ^c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Bortezomib; Free light chains; Monoclonal gammopathy of renal significance; Monoclonal immunoglobulin; Monoclonal immunoglobulin deposition disease

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; MALE; MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; PARAPROTEINEMIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; GLOMERULUS BASEMENT MEMBRANE; IMMUNOLOGY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL RATE; WALDENSTROM MACROGLOBULINEMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR BASEMENT MEMBRANE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEINURIA; RETROSPECTIVE STUDIES; SURVIVAL RATE; THALIDOMIDE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84947563375     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.201     Document Type: Article

References (42)

1. Preud'homme JL, Aucouturier P, Touchard G et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46: 965-972.
2. Ronco PM, Alyanakian MA, Mougenot B et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001; 12: 1558-1565.
3. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-1492.
4. Pozzi C, D'Amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154-1163.
5. Nasr SH, Valeri AM, Cornell LD et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7: 231-239.
6. Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87: 698-711.
7. Denoroy L, Déret S, Aucouturier P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol Lett 1994; 42: 63-66.
8. Sicard A, Karras A, Goujon J-M et al. Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. Nephrol Dial Transplant 2014; 29: 1894-1902.
9. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292-4295.
10. Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013; 122: 3583-3590.
11. Leung N, Lager DJ, Gertz MA et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43: 147-153.
12. Gerlag PG, Koene RA, Berden JH. Renal transplantation in light chain nephropathy: case report and review of the literature. Clin Nephrol 1986; 25: 101-104.
13. Alchi B, Nishi S, Iguchi S et al. Recurrent light and heavy chain deposition disease after renal transplantation. Nephrol Dial Transplant 2005; 20: 1487-1491.
14. Horike K, Takeda A, Otsuka Y et al. A case of recurrent light chain deposition disease after living-related renal transplantation-detailed process of the recurrence. Clin Transplant 2012; 26: 64-69.
15. Tanenbaum ND, Howell DN, Middleton JP, Spurney RF. Lambda light chain deposition disease in a renal allograft. Transplant Proc 2005; 37: 4289-4292.
16. Royer B, Arnulf B, Martinez F et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648.
17. Gharwan H, Truica CI. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 2012; 29: 1197-1201.
18. Tovar N, Cibeira MT, Rosiñol L et al. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for lightchain deposition disease. Eur J Haematol 2012; 89: 340-344.
19. Kaposztas Z, Kahan BD, Katz SM et al. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc 2009; 41: 4407-4410.
20. Patel K, Dillon JJ, Leung N et al. Use of bortezomib in heavy-chain deposition disease: a report of 3 cases. Am J Kidney Dis 2014; 64: 123-127.
21. Moiz A, Javed T, Garces J et al. Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report. Ochsner J 2014; 14: 445-449.
22. Kastritis E, Migkou M, Gavriatopoulou M et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009; 94: 300-302.
23. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
24. Dimopoulos MA, Roussou M, Gavriatopoulou M et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomibbased regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009; 9: 302-306.
25. Morabito F, Gentile M, Ciolli S et al. Safety and efficacy of bortezomibbased regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010; 84: 223-228.
26. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: 4635-4641.
27. Dimopoulos MA, Roussou M, Gkotzamanidou M et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27: 423-429.
28. Nambirajan A, Bhowmik D, Singh G et al. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. Transpl Int 2015; 28: 375-379.
29. Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
30. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440.
31. Venner CP, Lane T, Foard D et al. Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
32. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamidebortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 19: 4391-4394.
33. Jaccard A, Comenzo RL, Hari P et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014; 99: 1479-1485.
34. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 144: 822-829.
35. Knudsen LM, Nielsen B, Gimsing P et al. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33.
36. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
37. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
38. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
39. Durie BGM, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
40. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
41. Bridoux F, Hugue V, Coldefy O et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62: 1764-1775.
42. Beaume A, Brizard A, Dreyfus B et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 1216-1219.